Press release
May 5, 2026
BioNTech Announces First Quarter 2026 Financial Results and Corporate Update
BioNTech SE (BNTX)
Five additional pivotal trials for pumitamig initiated during 2026 in collaboration with Bristol Myers Squibb Oncology pipeline strength and combination strategy highlighted through multiple clinical data updates, including pumitamig, gotistobart and antibody-drug conjugate programs Catalyst-rich